Researchers in Michael Sigals lab at the Max Delbruck Center and Charite - Universitatsmedizin Berlin have discovered the ...

The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum ...

Vedolizumab (Entyvio) and infliximab (Remicade) led to mostly similar 1-year outcomes in patients with ulcerative colitis ...

A simple, non-invasive treatment focused on the ears could one day provide relief for people with ulcerative colitis, a UM ...

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...

Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and ...

Understanding current trends in the incidence, prevalence, and distribution of ulcerative colitis can help inform diagnosis and treatment.

Topline Clinical Data Demonstrates Activity of SOR102 Across Multiple Clinical Endpoints Supporting Advancement to Phase 2 ...

Researchers have uncovered potentially diagnostic gut microbiome signatures and metabolic pathways associated specifically ...

Upadacitinib may offer superior disease management than tofacitinib for patients with ulcerative colitis. Learn more.

Teva and its partner Sanofi say 47.8% of patients with ulcerative colitis who received a high dose of their drug duvakitug experienced clinical remission, compared with 20.5% who received a placebo.

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most ...